An analysis conducted by the nonprofit Institute for Clinical and Economic Review (ICER) showed the cost-effectiveness of Amarin’s (AMRN +0.7%)
Vascepa (icosapent ethyl) across all of its criteria, including its
most stringent standard. ICER’s review was based on results from the
REDUCE-IT study.
A separate independent cost-effectiveness analysis
will be presented at the American Heart Association Scientific Sessions
next month in Philadelphia. The effort was funded by an unrestricted
grant from the company.
Amarin’s U.S. application for a CV benefit claim is currently under FDA review with an action date of December 28.
https://seekingalpha.com/news/3506549-analysis-shows-cost-effectiveness-amarins-vascepa
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.